NASDAQ:RXRX Recursion Pharmaceuticals Q3 2025 Earnings Report $5.91 -0.18 (-2.96%) Closing price 04:00 PM EasternExtended Trading$5.98 +0.08 (+1.27%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Recursion Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.35Beat/MissN/AOne Year Ago EPSN/ARecursion Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$19.36 millionBeat/MissN/AYoY Revenue GrowthN/ARecursion Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Recursion Pharmaceuticals Earnings HeadlinesRecursion Pharmaceuticals: Recent Gains Are Mysterious Given A Lack Of Overall ProgressOctober 9 at 11:22 AM | seekingalpha.comRecursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI ConferenceOctober 9 at 6:31 AM | insidermonkey.comBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.October 9 at 2:00 AM | Crypto 101 Media (Ad)Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory October 8 at 12:10 PM | insidermonkey.comRecursion Pharmaceuticals, Inc. (RXRX): A Bull Case TheoryOctober 8 at 11:30 AM | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should KnowOctober 7 at 10:59 PM | msn.comSee More Recursion Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Recursion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recursion Pharmaceuticals and other key companies, straight to your email. Email Address About Recursion PharmaceuticalsRecursion Pharmaceuticals (NASDAQ:RXRX) (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed. At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations. These data feed into proprietary machine-learning pipelines designed to uncover subtle phenotypic changes that traditional screening methods might miss. The company applies this approach to diverse therapeutic areas, including rare genetic diseases, oncology and immunology, with several preclinical programs in its pipeline. Partnerships with pharmaceutical firms and research institutions further extend Recursion’s reach and validate its platform in real-world drug discovery projects. Founded in 2013 by Christopher Gibson and Blake Borgeson, Recursion Pharmaceuticals is headquartered in Salt Lake City, Utah, and maintains additional research facilities and corporate offices across North America and Europe. Following its initial public offering in early 2021, the company has continued to expand both its technological capabilities and its therapeutic focus. Led by CEO Christopher Gibson and a management team versed in biology, data science and automation engineering, Recursion is positioned to advance a new paradigm in drug discovery that bridges experimental data with predictive, AI-driven insights.View Recursion Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
